Condition: Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal Neoplasms · Sponsor: Merck Sharp & Dohme LLC
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927) | Tucson, Arizona, United States | Recruiting |
| UCLA Hematology/Oncology - Santa Monica ( Site 6905) | Los Angeles, California, United States | Recruiting |
| Norton Hospital-Norton Cancer Institute - Downtown ( Site 6900) | Louisville, Kentucky, United States | Completed |
| The Cancer and Hematology Centers ( Site 6912) | Grand Rapids, Michigan, United States | Recruiting |
| Hematology-Oncology Associates of Central NY, P.C. ( Site 6925) | East Syracuse, New York, United States | Recruiting |
| Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 6907) | New York, New York, United States | Completed |
| UPMC Hillman Cancer Center-UPMC ( Site 6904) | Pittsburgh, Pennsylvania, United States | Recruiting |
| University of Texas MD Anderson Cancer Center ( Site 6920) | Houston, Texas, United States | Recruiting |
| Liga Norte Riograndense Contra o Câncer ( Site 6303) | Natal, Rio Grande do Norte, Brazil | Recruiting |
| Hospital Nossa Senhora da Conceição ( Site 6301) | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
| ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 6300) | São Paulo, Brazil | Recruiting |
| IBCC - Instituto Brasileiro de Controle do Câncer ( Site 6304) | São Paulo, Brazil | Recruiting |
+ 39 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06469944